Singapore markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
12.02+0.25 (+2.12%)
As of 3:35PM EDT. Market open.
Sign in to post a message.
  • K
    K
    Catalyst

    1. NDA for HTX-019 (treatment of post op N/V) in December. (5B target market)

    2. E.U. partnership and launch of zynrelef in E.U. expected q1 22. (Acquisition vs. Merger)

    3. HTX-034 data read out (5d pain management)

    4. Zynrelef product specific c-code expected by Oct 1st.

    5. Zynrelef permanent j-code expected by Jan 1st.

    6. Zynrelef enrollment in spine study.

    7. Announcement of zynrelef on total shoulder arthroplasty study.

    8. Zynrelef label expansion requirements from FDA. (Not as significant as independent studies for zynrelef. Example zynrelef in total hip arthroplasty.) Once published reps can promote those studies and insurances will reimburse based on the evidence.)

    9. NOPAIN act currently in the senate. Will provide seperate reimbursement of non-opioids.

    10. NOD act currently in senate. Allows patients to opt out of opioid treatment and informs them of alternative options. (Provides reimbursement for those options a.k.a zynrelef.)

    Above all ZYNRELEF sales!!
  • R
    Ray
    Repeat of yesterday. It's almost as if the shorts wait for the volume to decrease and then sell the gap to bring the price down... Sure looks like HRTX is trying to break out though... 12 seems to be the magic number.
  • M
    Mike
    Cantor analyst Brandon Folkes sees further growth ahead for this stock, writing: “We continue to believe HRTX stock offers investors a favorable risk/reward at current levels. We remain bullish on the peak sales potential for Zynrelef, even if we expect a measured launch near term. The chemotherapy-induced nausea and vomiting (CINV) franchise continues to grow, albeit at a revised trajectory. With this growth in the CINV franchise [and] strong early Zynrelef launch metrics… we believe the company will drive value for investors…”
    These bullish comments back up an Overweight (i.e. Buy) rating, and a $26 price target that implies an upside potential of ~118% over the next 12 months. (To watch Folkes’ track record, click here)
    Folkes is no outlier in his views of Heron; the company has picked up 4 positive reviews recently, making the Strong Buy consensus rating unanimous. The shares are trading for $11.91 and have an average price target of $27.50, suggesting a robust upside of 131%
  • M
    Mike
    Dr. Jacques Chelly to Receive Funding to Establish Heron Therapeutics Center of Excellence

    Posted on August 27, 2021
     
    Congratulations to Principal Investigator Jacques E. Chelly, MD, PhD, MBA, who will receive funding to establish a Center of Excellence with Heron Therapeutics. This multidisciplinary center will be dedicated to education and research related to perioperative pain management with a special focus on non-opioid approaches and minimization of opioid prescription. The current funding will support a pilot program entitled “Pennsylvania Center of Opioid Prescribing Stewardship (P-COPS),” a collaborative effort between anesthesiologists and surgeons, including Drs. Aman Mahajan and Shiv Goel (Anesthesiology & Perioperative Medicine); Benjamin Davies and Bruce Jacobs (Urology), and Matthew Holtzman (Surgical Oncology). The goal is to optimize opioid prescription during the perioperative period, including after discharge, through the education and monitoring of patients, surgeons, anesthesiologists, and other health care professionals. The program will initially develop at UPMC Shadyside with the goal is to secondarily expand to UPMC Magee-Womens Hospital, UPMC Passavant, and other UPMC hospitals.  
  • M
    Mike
  • M
    Mike
    Effective with date of service July 1, 2021, the Medicaid and NC Health Choice programs cover bupivacaine and meloxicam extended-release solution, for soft tissue or periarticular instillation use (Zynrelef™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3490 - Unclassified drugs
  • M
    Mike
    form s was filed that could have been the movement change
  • M
    Mike
    go to utube and type in "at a time when drug overdose is climbing" interview about zynrelef
  • D
    Daulet
    We went on a straight path with a potential of 350%. BPT crossed the resistance line yesterday! Oil has gone beyond the payback, which indicates a correct and irreversible trend. The recommendation is to buy at current prices.
  • J
    Jst.CA$H
    When the dam breaks, water will flow...
  • p
    pohlmeyer
    The 7 Best Lithium Stocks - These Stocks Could 10X For details https://youtu.be/0mlWl2t91EY
  • M
    Mike
    It would be nice to hear some positive feedback about the presentation at the American Academy of Orthopaedic Surgeons Annual Meeting.
  • M
    Mike
    American Academy of Orthopaedic Surgeons 2021 Annual Meeting. Heron Therapeutics presenting "The Future of Postoperative Pain Management in Orthopaedics" Glad to see Heron in a key time slot presenting a lunch and learn. (Wed Sept 1st 12:40-1:25)
  • J
    Joe
    Heron’s price is not low on accident. This has become a risky investment as they need sales of all of all their drugs to become a profitable company and avoid BK. They will need more $$$ too!
    Hearing an update on label expansion would be great. I don’t think Wall Street has a lot of faith in what BQ and his team. They said that the $150M they received would take them to profitability. Don’t think that is the case.
    I still believe that Zynrelef can sell $500M to $1B a year. Just wish I knew the time table on that.
  • M
    Mike
    A bit heavier volume this morning and green. Curious to see if we can close above 12.
  • A
    Anonymous
    When do you all think HRTX will reach $5 billion market cap … sometime in 2022 with all the good things happening. Wowser!
  • J
    Joe
    Will we ever close above 12?
  • M
    Mike
    Think today is just the market in general. Held up better than most.
  • M
    Mike
    Small-Cap Biotech Stocks Play Catch Up With Industry Leaders

    (Bloomberg) -- Small-cap biotech stocks are lagging this year with the spotlight squarely on their larger rivals who have been in a position to supply the world with Covid-19 shots and treatments.
    Pfizer Inc. reached record highs on news last week that the White House would issue new guidance for booster shots, while its vaccine partner BioNTech SE and Moderna Inc., also making virus inoculations, have delivered triple-digit gains this year. Small-cap biotech stocks by contrast are down for the year, based on various measures, but analysts and investors expect this cohort of the sector will soon play catch up.
    “It’s a question of when it recovers,” Jason Butler, an analyst at JMP Securities, said in an interview. “Not if it recovers.”

    For one, gains for biotech stocks have historically been led by the larger companies with the rest of the group following. And potential catalysts for small-caps exist ahead including positive results in clinical trials and clarity out of Washington on market-moving issues like mergers and acquisitions and drug pricing regulation.
    The market-weighted Nasdaq Biotech Index is up 8.7% year to date due largely to Moderna, while the SPDR S&P Biotech ETF, which tracks the equal-weighted S&P Biotechnology Select Industry Index and is seen as more of a proxy for small caps, has declined 13% year-to-date. In the Russell 2000, the health-care sector is the only one in the red for the year with an 8.7% decline.
    The recent underperformance comes amid heightened competition for investors’ dollars, according to Oppeinheimer analyst Hartaj Singh. Those who focus on biotechs have had a healthy crop of initial public offerings, splitting their attention with a slew of existing biotechs. July marked a record month for the number of these deals in the U.S., according to data compiled by Bloomberg.

    Generalists have turned to the safer bets, especially large players working on coronavirus therapies. Some investors see an “easy opportunity to make money off of companies like BioNTech and Moderna,” Patrick Nosker, director of research for Affinity Asset Advisors, said in an interview.
    Still, overall gaps between small and large caps historically don’t last long. JMP’s Butler said the successes of the large companies tend to signal that smaller ones are soon to follow suit. During downturns in 2015 and at the end of 2018, larger-cap biotechs led the recovery, followed closely by their smaller counterparts,